Study registration: *
Publication Lefevre B, medRxiv, 2021
Dates: 2021-01-15 to 2021-05-19
Funding: Public/non profit (French Ministry of Health and Solidarity)
Conflict of interest: no COI (Benjamin Lefevre reports travel funding from ViiV (2019) and Gilead (2020), outside the submitted work. All other authors have no competing interests.)

Methods

Study design:Cohort
Description of participants: Adults including elderly in 5 centres in France.
Inclusion criteria:
  • (LTCFs) in which any SARS-CoV-2 outbreak that implicated B.1.351 had been documented between 15 January and 16 April 2021. In each LTCF, all residents were eligible for inclusion.

Exclusion criteria:
  • NR

Follow-up duration (months): 4.1
Vaccines:
  • 1 or 2 doses of BNT162b2
Variant description :
Variant name: Beta
Evidence: Indirect evidence (prevalence of variant in the population: *)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: Yes
Data accessibility: The data that support the findings of this study are available from the Societe de Pathologie Infectieuse de Langue Francaise. Restrictions apply to the availability of these data, which were used under authorized agreement for this study by the Societe de Pathologie Infectieuse de Langue Francaise, which ensures compliance with data protection regulations in France.
General comment Concerns mainly about the possibility of uncontrolled confounding.